PAI-1 Expression in Non-scarring Hair Loss

Status Terminated

Clinical Trial Summary

This study will investigate whether subjects who suffer from hair loss have increased levels of PAI-1 compared to age-matched control subjects. The level of PAI-1 expression will be determined in subjects without hair loss and in subjects with non-scarring hair loss, including androgenetic alopecia, telogen effluvium and alopecia areata.

Clinical Trial Description

This study will compare the levels of PAI-1 expression in subjects with different forms of non-scarring hair loss and in these subjects vs normal age-matched controls. Hair loss subjects will have their Northwestern Memorial Hospital and Northwestern Medical Faculty Foundation medical records reviewed to ensure they meet inclusion and exclusion criteria. All subjects will have a 4 mm punch biopsy on the scalp. Tissue PAI-1 levels from scalp skin biopsies will be determined by immunohistochemical staining. Samples will be kept for approximately 15 years, after which time unused samples will be destroyed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02548689
Study type	Observational
Source	Northwestern University
Contact
Status	Terminated
Phase
Start date	July 2015
Completion date	June 2021

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05051761` - Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata	Phase 3
Active, not recruiting	`NCT03570749` - A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata	Phase 2/Phase 3
Completed	`NCT02812342` - Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants	Phase 2
Completed	`NCT02350023` - Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata	Phase 4
Completed	`NCT02018042` - An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata	Phase 2
Terminated	`NCT01898806` - Intralesional Steroids in the Treatment of Alopecia Areata	Phase 4
Recruiting	`NCT04011748` - Clinical Application of Stem Cell Educator Therapy in Alopecia Areata	Phase 2
Active, not recruiting	`NCT04517864` - PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA	Phase 2
Not yet recruiting	`NCT05803070` - Topical Cetirizine in Treatment of Localized Alopecia Areata
Not yet recruiting	`NCT05496426` - A Study of KL130008 in Adults With Severe Alopecia Areata	Phase 2
Completed	`NCT04147845` - Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata	N/A
Terminated	`NCT03325296` - Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.	Phase 2
Recruiting	`NCT05635266` - A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Enrolling by invitation	`NCT05745389` - CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
Recruiting	`NCT04246372` - Tofacitinib for Immune Skin Conditions in Down Syndrome	Phase 2
Not yet recruiting	`NCT06087796` - Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.	Phase 1
Withdrawn	`NCT03532958` - Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata	Phase 2
Recruiting	`NCT02604888` - Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females	N/A
Terminated	`NCT01385839` - Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata	N/A
Completed	`NCT00408798` - Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin	N/A